Therapeutic Asset Ratings

462 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Interleukin 18 (recombinant human mutein clone ST-067) Neoplasm	Simcha IL-18, Inc.	P1/2	CC (40)
INX315 Neoplasm	Incyclix Bio	P1/2	CC (40)
ipg1094 Neoplasm	Nanjing Immunophage Biotech Co., Ltd	P1/2	CC (40)
ipn01194 Neoplasm	Ipsen	P1/2	CC (40)
Ixovex-1 Neoplasm	Psivac Ltd	P1/2	CC (40)
js207 Neoplasm	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (40)
kn046 Neoplasm	Suzhou Kintor Pharmaceutical Inc,	P1/2	CC (40)
Limertinib Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (40)
Mdna11 Neoplasm	Medicenna Therapeutics, Inc.	P1/2	CC (40)
Muzastotug Neoplasm	Sanofi	P1/2	CC (40)
Necvax-Neo1 Neoplasm	NEC Bio B.V	P1/2	CC (40)
Omx-0407 Neoplasm	iOmx Therapeutics AG	P1/2	CC (40)
Otx-2002 Neoplasm	Omega Therapeutics	P1/2	CC (40)
PEXMETINIB Neoplasm	Dan Zandberg	P1/2	CC (40)
PRS-344 Neoplasm	Servier Bio-Innovation LLC	P1/2	CC (40)
Pucotenlimab Neoplasm	Binhui Biopharmaceutical Co., Ltd.	P1/2	CC (40)
ql1203 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
ql2107 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
qls31905 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
rc148 Neoplasm	RemeGen Co., Ltd.	P1/2	CC (40)
rc48 Solid Tumor	RemeGen Co., Ltd.	P1/2	CC (40)
Rx-Af01 Neoplasm	Sun Yat-sen University	P1/2	CC (40)
S095012 Neoplasm	Servier Bio-Innovation LLC	P1/2	CC (40)
s241656 Neoplasm	Institut de Recherches Internationales Servier	P1/2	CC (40)
sa53-os Neoplasm	Lamassu Bio Inc	P1/2	CC (40)

Showing 176 to 200 of 462 assets